Singapore markets close in 4 hours 13 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
589.60-2.55 (-0.43%)
At close: 4:00PM EDT
Sign in to post a message.
  • H
    Humble Warrior
    Honestly, I feel this is one of the last times, you are going to see REGN trading in $550-600 range unless some life shattering event like pandemic happens again. I picked up few shares last week at $560. In wake of back to back recent positive news for dupixent, I think its going to become a drug in a pipeline in itself. Not to mention, other strong brands like Eyelea, Libtayo etc and more coming from the pipeline!
  • t
    theubiquitousman
    Is it possible a bigger pharma company would try to work out a merger with REGN? I can see some logic
    in it for the right "player".
  • J
    Juan
    Atea Pharmaceuticals/Roche's Covid antiviral pill failed in phase 3 trials. It had the same impact as the placebo. They are saying it may have been the test design so they are going to redo it but it will delay results for a year. Also, there is renewed concern that these drugs are mutagenic and will cause cancer. Even Merck now say their antiviral may cause cancer but they believe not from short term use.

    Would you take a pill that has cancer as a potential side effect?
  • C
    Costy
    Dupixent will become the most widely used pharmaceutical drug 💉 on the planet during the top half of this decade. Not just my opinion. A recent Barron's article has the same sentiment.
  • J
    Juan
    REGN was upgraded today by Leerink. 798 price target
  • P
    Prem
    The stars are all aligned for this stock; at the moment it is Dupi across multiple type-2 inflammation indications at the moment but soon it will be their likely to be best in class PD-1 inhibitor drug Libtayo (with multiple interesting combination therapies undergoing clinical trials) which will eventually prove to be even better than Merck’s first in class PD-1 inhibitor Keytruda

    After that will be the turn of gene therapies being currently developed in collaboration with Intellia, and Roche, and so on

    The only cloud hanging on this stock is the Medicare drug price negotiation legislation that is slowly sputtering through congress; this makes it impossible to put a confident value on their pipeline
  • A
    Anonymous
    REGN is a great science-driven biologics discovery organization, and I love that they're expanding into more therapeutic areas. But an issue that remains in my mind from their blockbuster ophthalmology area is the patent life of Eylea. It comprises such a large portion of their product revenue that there's a looming concern of competition from biosimilars. Can anyone share when Eylea patent protection will expire, and their thoughts on the competitive threat to that blockbuster product?
  • J
    Juan
    We're up 30 points from the week's lows already. With earnings approaching, this stock can relatively quickly make up the 17% loss last month
  • H
    Humble Warrior
    Another positive trial result for dupixent! Easy peasy getting this past regulatory hurdle as dupixent has now well established safety and efficacy profile. Another revenue stream. Another source for EPS growth in years to come.
  • J
    Juan
    ARKG sold 15,000 shares on REGN holdings on Friday. They definitely have been selling consistently but it's not enough to cause this kind of downtrend. I usually have a feel for what's going on but I really have no idea what's moving the stock right now and neither does anyone I talk to
  • J
    Juan
    In the past 6 months ARKG has dumped 1.5 million shares of REGN. That absolutely has suppressed the price some. Wood only holds 290,000 shares now so this dynamic is nearing its endpoint. She sold a lot more today.
  • J
    Juan
    REGN this week erased one third of the month long decline total. It went up despite the vaccine stocks tanking today. I think the call on Nov 4 will be very positive for the stock
  • E
    Ed
    REGN's Chief Scientific Officer George Yancopoulos made a controversial statement at a medical conference that Colin Powell could have been saved had he been given REGEN-COV instead of a vaccine since he he was immunocompromised and could not produce his own antibodies. Further, he said that the emphasis of vaccines to the exclusion of monoclonal antibodies has cost tens of thousands of lives. Tragedy that even people at the highest level are not getting access to this treatment.
  • J
    Juan
    Dupixent just got expanded FDA approved use for children. That's why there was a little after hours pop
  • J
    Juan
    I'm definitely holding thru earnings and probably for another 11 months at least. You have to trust your research not the price or you will end up panic selling all the time. If I lose money, at least it would have been because I was wrong not because I was emotional
  • J
    Juan
    Minor pipeline news- NTLA-2001 was granted orphan drug status and should move into phase 2 trials stage soon. It would be one of the few impactful treatments for a rare disease "familial amyloidosis" Larger picture- the (Intellia) crispr partnership are going to pay off soon
  • J
    Juan
    Volume spiked up at the close with an uptrend in price. Reassuring day. A lot of large institutional buys in the morning and it maintained those gains
  • R
    Rex
    Close to 574 which is the next technical point on the chart.
  • R
    Renato
    $INO conversation
    Goodbye INO! Ahhahahahah
    Regeneron Pharmaceuticals: FDA Accepts REGEN-COV for Priority Review for Treatment and Prophylaxis of Covid-19
    $REGN
  • J
    Juan
    I won't sell unless I understand why it's down and it would be huge loss at this point. I made it my second largest holding which is a tremendous amount of money. Unless there are failureS in the pipeline- I think I just hold for a long time. Volume is high. It's independently tanking by that I mean it's not following any biotech index. Their performance is worse. It's frustrating because there is no obvious catalyst right now so it's hard to make a decision